Bristol-Myers' Mike Burgess Talks R&D Challenges, Portfolio Developments In 2017
Executive Summary
Dr. Mike Burgess, the head of several disease R&D areas at Bristol-Myers Squibb, talks to Scrip on the side lines of the recent One Nucleus Genesis conference in London, UK, about the importance of a diverse portfolio, balancing R&D budgets and his industry-wide predictions for 2017.
You may also be interested in...
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.
Deals Shaping The Medical Industry, February 2021
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2021. Data provided by Biomedtracker.
In Vivo’s Deals Of The Year 2020: Winners Revealed
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
Need a specific report? 1000+ reports available
Buy Reports